ParkinsonFranceV1, PascalFrancis, Curation, bibRecord, 000759

Granulocyte colony-stimulating factor is not protective against selective dopaminergic cell death in vitro

Identifieur interne : 000759 ( PascalFrancis/Curation ); précédent : 000758; suivant : 000760

Granulocyte colony-stimulating factor is not protective against selective dopaminergic cell death in vitro

Auteurs : Carmen Henze [France] ; Thomas Lescot [France] ; Sabine Traver [France] ; Bénédicte Salthun-Lassalle [France] ; Etienne C. Hirsch [France] ; Patrick P. Michel [France] ; Andreas Hartmann [France]

Source :

Neuroscience letters [ 0304-3940 ] ; 2005.

RBID : Pascal:05-0298051

Descripteurs français

Pascal (Inist)
- Granulocyte, Facteur stimulant colonie, Prévention, Dopamine, Mort cellulaire, In vitro, Parkinson maladie.

English descriptors

KwdEn :
- Cell death, Colony stimulating factor, Dopamine, Granulocyte, In vitro, Parkinson disease, Prevention.

Abstract

In the present study, we evaluated the potential neuroprotective effect of granulocyte colony-stimulating factor (G-CSF), a hematopoietic growth factor in two different culture models in which dopaminergic (DA) neurons die selectively: first, in a culture model in which death of DA neurons occurs spontaneously and second, in a toxin-based paradigm, the in vitro l-methyl-4-phenylpyridinium model of PD. In neither of the two models, a treatment with G-CSF, could prevent or halt the progressive neurodegeneration. However, we cannot rule out that G-CSF might exert neuroprotective or even deleterious effects in in vivo models of PD, based on the significant increase in the number of microglial cells observed after G-CSF treatment.

A01	`01`	`1`		`@0 0304-3940`
A02	`01`			`@0 NELED5`
A03		`1`		`@0 Neurosci. lett.`
A05				`@2 383`
A06				`@2 1-2`
A08	`01`	`1`	`ENG`	`@1 Granulocyte colony-stimulating factor is not protective against selective dopaminergic cell death in vitro`
A11	`01`	`1`		`@1 HENZE (Carmen)`
A11	`02`	`1`		`@1 LESCOT (Thomas)`
A11	`03`	`1`		`@1 TRAVER (Sabine)`
A11	`04`	`1`		`@1 SALTHUN-LASSALLE (Bénédicte)`
A11	`05`	`1`		`@1 HIRSCH (Etienne C.)`
A11	`06`	`1`		`@1 MICHEL (Patrick P.)`
A11	`07`	`1`		`@1 HARTMANN (Andreas)`
A14	`01`			`@1 INSERM U 679 (former U 289), Experimental Neurology and Therapeutics, Centre d'Investigation Clinique, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital @2 75651 Paris @3 FRA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut.`
A20				`@1 44-48`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 17240 @5 354000138241730090`
A44				`@0 0000 @1 © 2005 INIST-CNRS. All rights reserved.`
A45				`@0 15 ref.`
A47	`01`	`1`		`@0 05-0298051`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Neuroscience letters`
A66	`01`			`@0 IRL`
C01	`01`		`ENG`	@0 In the present study, we evaluated the potential neuroprotective effect of granulocyte colony-stimulating factor (G-CSF), a hematopoietic growth factor in two different culture models in which dopaminergic (DA) neurons die selectively: first, in a culture model in which death of DA neurons occurs spontaneously and second, in a toxin-based paradigm, the in vitro l-methyl-4-phenylpyridinium model of PD. In neither of the two models, a treatment with G-CSF, could prevent or halt the progressive neurodegeneration. However, we cannot rule out that G-CSF might exert neuroprotective or even deleterious effects in in vivo models of PD, based on the significant increase in the number of microglial cells observed after G-CSF treatment.
C02	`01`	`X`		`@0 002A25`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Granulocyte @5 01`
C03	`01`	`X`	`ENG`	`@0 Granulocyte @5 01`
C03	`01`	`X`	`SPA`	`@0 Granulocito @5 01`
C03	`02`	`X`	`FRE`	`@0 Facteur stimulant colonie @5 02`
C03	`02`	`X`	`ENG`	`@0 Colony stimulating factor @5 02`
C03	`02`	`X`	`SPA`	`@0 Factor estimulante colonia @5 02`
C03	`03`	`X`	`FRE`	`@0 Prévention @5 03`
C03	`03`	`X`	`ENG`	`@0 Prevention @5 03`
C03	`03`	`X`	`SPA`	`@0 Prevención @5 03`
C03	`04`	`X`	`FRE`	`@0 Dopamine @2 NK @2 FR @5 04`
C03	`04`	`X`	`ENG`	`@0 Dopamine @2 NK @2 FR @5 04`
C03	`04`	`X`	`SPA`	`@0 Dopamina @2 NK @2 FR @5 04`
C03	`05`	`X`	`FRE`	`@0 Mort cellulaire @5 05`
C03	`05`	`X`	`ENG`	`@0 Cell death @5 05`
C03	`05`	`X`	`SPA`	`@0 Muerte celular @5 05`
C03	`06`	`X`	`FRE`	`@0 In vitro @5 06`
C03	`06`	`X`	`ENG`	`@0 In vitro @5 06`
C03	`06`	`X`	`SPA`	`@0 In vitro @5 06`
C03	`07`	`X`	`FRE`	`@0 Parkinson maladie @5 09`
C03	`07`	`X`	`ENG`	`@0 Parkinson disease @5 09`
C03	`07`	`X`	`SPA`	`@0 Parkinson enfermedad @5 09`
C07	`01`	`X`	`FRE`	`@0 Catécholamine @5 20`
C07	`01`	`X`	`ENG`	`@0 Catecholamine @5 20`
C07	`01`	`X`	`SPA`	`@0 Catecolamina @5 20`
C07	`02`	`X`	`FRE`	`@0 Neurotransmetteur @5 21`
C07	`02`	`X`	`ENG`	`@0 Neurotransmitter @5 21`
C07	`02`	`X`	`SPA`	`@0 Neurotransmisor @5 21`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 22`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 22`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 22`
C07	`04`	`X`	`FRE`	`@0 Système nerveux pathologie @5 23`
C07	`04`	`X`	`ENG`	`@0 Nervous system diseases @5 23`
C07	`04`	`X`	`SPA`	`@0 Sistema nervioso patología @5 23`
C07	`05`	`X`	`FRE`	`@0 Encéphale pathologie @5 24`
C07	`05`	`X`	`ENG`	`@0 Cerebral disorder @5 24`
C07	`05`	`X`	`SPA`	`@0 Encéfalo patología @5 24`
C07	`06`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 25`
C07	`06`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 25`
C07	`06`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 25`
C07	`07`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 26`
C07	`07`	`X`	`ENG`	`@0 Central nervous system disease @5 26`
C07	`07`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 26`
N21				`@1 206`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000C75

Links to Exploration step

Pascal:05-0298051

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Granulocyte colony-stimulating factor is not protective against selective dopaminergic cell death in vitro</title>
<author><name sortKey="Henze, Carmen" sort="Henze, Carmen" uniqKey="Henze C" first="Carmen" last="Henze">Carmen Henze</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U 679 (former U 289), Experimental Neurology and Therapeutics, Centre d'Investigation Clinique, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Lescot, Thomas" sort="Lescot, Thomas" uniqKey="Lescot T" first="Thomas" last="Lescot">Thomas Lescot</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U 679 (former U 289), Experimental Neurology and Therapeutics, Centre d'Investigation Clinique, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Traver, Sabine" sort="Traver, Sabine" uniqKey="Traver S" first="Sabine" last="Traver">Sabine Traver</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U 679 (former U 289), Experimental Neurology and Therapeutics, Centre d'Investigation Clinique, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Salthun Lassalle, Benedicte" sort="Salthun Lassalle, Benedicte" uniqKey="Salthun Lassalle B" first="Bénédicte" last="Salthun-Lassalle">Bénédicte Salthun-Lassalle</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U 679 (former U 289), Experimental Neurology and Therapeutics, Centre d'Investigation Clinique, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Hirsch, Etienne C" sort="Hirsch, Etienne C" uniqKey="Hirsch E" first="Etienne C." last="Hirsch">Etienne C. Hirsch</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U 679 (former U 289), Experimental Neurology and Therapeutics, Centre d'Investigation Clinique, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Michel, Patrick P" sort="Michel, Patrick P" uniqKey="Michel P" first="Patrick P." last="Michel">Patrick P. Michel</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U 679 (former U 289), Experimental Neurology and Therapeutics, Centre d'Investigation Clinique, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Hartmann, Andreas" sort="Hartmann, Andreas" uniqKey="Hartmann A" first="Andreas" last="Hartmann">Andreas Hartmann</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U 679 (former U 289), Experimental Neurology and Therapeutics, Centre d'Investigation Clinique, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0298051</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0298051 INIST</idno>
<idno type="RBID">Pascal:05-0298051</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000C75</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000759</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Granulocyte colony-stimulating factor is not protective against selective dopaminergic cell death in vitro</title>
<author><name sortKey="Henze, Carmen" sort="Henze, Carmen" uniqKey="Henze C" first="Carmen" last="Henze">Carmen Henze</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U 679 (former U 289), Experimental Neurology and Therapeutics, Centre d'Investigation Clinique, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Lescot, Thomas" sort="Lescot, Thomas" uniqKey="Lescot T" first="Thomas" last="Lescot">Thomas Lescot</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U 679 (former U 289), Experimental Neurology and Therapeutics, Centre d'Investigation Clinique, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Traver, Sabine" sort="Traver, Sabine" uniqKey="Traver S" first="Sabine" last="Traver">Sabine Traver</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U 679 (former U 289), Experimental Neurology and Therapeutics, Centre d'Investigation Clinique, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Salthun Lassalle, Benedicte" sort="Salthun Lassalle, Benedicte" uniqKey="Salthun Lassalle B" first="Bénédicte" last="Salthun-Lassalle">Bénédicte Salthun-Lassalle</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U 679 (former U 289), Experimental Neurology and Therapeutics, Centre d'Investigation Clinique, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Hirsch, Etienne C" sort="Hirsch, Etienne C" uniqKey="Hirsch E" first="Etienne C." last="Hirsch">Etienne C. Hirsch</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U 679 (former U 289), Experimental Neurology and Therapeutics, Centre d'Investigation Clinique, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Michel, Patrick P" sort="Michel, Patrick P" uniqKey="Michel P" first="Patrick P." last="Michel">Patrick P. Michel</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U 679 (former U 289), Experimental Neurology and Therapeutics, Centre d'Investigation Clinique, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Hartmann, Andreas" sort="Hartmann, Andreas" uniqKey="Hartmann A" first="Andreas" last="Hartmann">Andreas Hartmann</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM U 679 (former U 289), Experimental Neurology and Therapeutics, Centre d'Investigation Clinique, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neuroscience letters</title>
<title level="j" type="abbreviated">Neurosci. lett.</title>
<idno type="ISSN">0304-3940</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neuroscience letters</title>
<title level="j" type="abbreviated">Neurosci. lett.</title>
<idno type="ISSN">0304-3940</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cell death</term>
<term>Colony stimulating factor</term>
<term>Dopamine</term>
<term>Granulocyte</term>
<term>In vitro</term>
<term>Parkinson disease</term>
<term>Prevention</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Granulocyte</term>
<term>Facteur stimulant colonie</term>
<term>Prévention</term>
<term>Dopamine</term>
<term>Mort cellulaire</term>
<term>In vitro</term>
<term>Parkinson maladie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In the present study, we evaluated the potential neuroprotective effect of granulocyte colony-stimulating factor (G-CSF), a hematopoietic growth factor in two different culture models in which dopaminergic (DA) neurons die selectively: first, in a culture model in which death of DA neurons occurs spontaneously and second, in a toxin-based paradigm, the in vitro l-methyl-4-phenylpyridinium model of PD. In neither of the two models, a treatment with G-CSF, could prevent or halt the progressive neurodegeneration. However, we cannot rule out that G-CSF might exert neuroprotective or even deleterious effects in in vivo models of PD, based on the significant increase in the number of microglial cells observed after G-CSF treatment.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0304-3940</s0>
</fA01>
<fA02 i1="01"><s0>NELED5</s0>
</fA02>
<fA03 i2="1"><s0>Neurosci. lett.</s0>
</fA03>
<fA05><s2>383</s2>
</fA05>
<fA06><s2>1-2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Granulocyte colony-stimulating factor is not protective against selective dopaminergic cell death in vitro</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>HENZE (Carmen)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LESCOT (Thomas)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>TRAVER (Sabine)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SALTHUN-LASSALLE (Bénédicte)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>HIRSCH (Etienne C.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MICHEL (Patrick P.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>HARTMANN (Andreas)</s1>
</fA11>
<fA14 i1="01"><s1>INSERM U 679 (former U 289), Experimental Neurology and Therapeutics, Centre d'Investigation Clinique, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital</s1>
<s2>75651 Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>44-48</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>17240</s2>
<s5>354000138241730090</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>15 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0298051</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Neuroscience letters</s0>
</fA64>
<fA66 i1="01"><s0>IRL</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>In the present study, we evaluated the potential neuroprotective effect of granulocyte colony-stimulating factor (G-CSF), a hematopoietic growth factor in two different culture models in which dopaminergic (DA) neurons die selectively: first, in a culture model in which death of DA neurons occurs spontaneously and second, in a toxin-based paradigm, the in vitro l-methyl-4-phenylpyridinium model of PD. In neither of the two models, a treatment with G-CSF, could prevent or halt the progressive neurodegeneration. However, we cannot rule out that G-CSF might exert neuroprotective or even deleterious effects in in vivo models of PD, based on the significant increase in the number of microglial cells observed after G-CSF treatment.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A25</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Granulocyte</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Granulocyte</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Granulocito</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Facteur stimulant colonie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Colony stimulating factor</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Factor estimulante colonia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Prévention</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Prevention</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Prevención</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Mort cellulaire</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Cell death</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Muerte celular</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>In vitro</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>In vitro</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>In vitro</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>09</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>20</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>20</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>20</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>21</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>21</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>21</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>22</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>22</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>22</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>23</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>23</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>23</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>24</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>24</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>24</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>25</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>25</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>25</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>26</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>26</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>26</s5>
</fC07>
<fN21><s1>206</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000759 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000759 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:05-0298051
   |texte=   Granulocyte colony-stimulating factor is not protective against selective dopaminergic cell death in vitro
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Granulocyte colony-stimulating factor is not protective against selective dopaminergic cell death in vitro

Granulocyte colony-stimulating factor is not protective against selective dopaminergic cell death in vitro

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri